Is Transgene Biotek a good stock to invest in?

Transgene Biotek can be analyzed on the following key metrics - TTM P/E: - Sector P/E: 49.32 Dividend Yield: 0% D/E ratio: -

Transgene Biotek Share Price

Sector: Biotechnology & Drugs

Powered by

4.42 -0.09 (-2.00%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 4.42

Today’s High 4.51

52 Week Low 3.22

52 Week High 10.84

Key Metrics

Market Cap (In Cr) 29.07
Beta 1.11
Div. Yield (%) 0
P/B -
TTM P/E -
Sector P/E 49.32
Open Price 4.51
Prev Close 4.51

View All Metrics

Transgene Biotek Analysis

Price Analysis

1 Week

3.03%
3 Months

31.94%
6 Month

-41.15%
YTD

-35.29%
1 Year

-50.28%

Risk Meter

49% Low risk
49% Moderate risk
49% Balanced Risk
49% High risk
49% Extreme risk

Transgene Biotek Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
0.26

Selling/ General/ Admin Expenses Total
0.31

Depreciation/ Amortization
0.09

Other Operating Expenses Total
1.08

Total Operating Expense
1.48

Operating Income
-1.22

Net Income Before Taxes
-0.68

Net Income
-0.68

Diluted Normalized EPS
-0.09

Period
2024

Total Revenue
0.23

Selling/ General/ Admin Expenses Total
0.31

Depreciation/ Amortization
0.09

Other Operating Expenses Total
0.54

Total Operating Expense
0.94

Operating Income
-0.71

Net Income Before Taxes
-0.66

Net Income
-0.66

Diluted Normalized EPS
-0.09

Period
2023

Total Revenue
0.06

Selling/ General/ Admin Expenses Total
0.3

Depreciation/ Amortization
4.95

Other Operating Expenses Total
0.74

Total Operating Expense
6.06

Operating Income
-6

Net Income Before Taxes
-6.01

Net Income
-6.01

Diluted Normalized EPS
-0.79

Period
2022

Total Revenue
0.09

Selling/ General/ Admin Expenses Total
0.29

Depreciation/ Amortization
9.92

Other Operating Expenses Total
0.31

Total Operating Expense
10.47

Operating Income
-10.39

Net Income Before Taxes
-10.4

Net Income
-10.4

Diluted Normalized EPS
-1.37

Period
2021

Total Revenue
0.17

Selling/ General/ Admin Expenses Total
0.25

Depreciation/ Amortization
9.91

Other Operating Expenses Total
0.39

Total Operating Expense
10.6

Operating Income
-10.44

Net Income Before Taxes
-10.43

Net Income
-10.43

Diluted Normalized EPS
-1.38

Period
2020

Total Revenue
0

Selling/ General/ Admin Expenses Total
0.29

Depreciation/ Amortization
9.9

Other Operating Expenses Total
0.56

Total Operating Expense
10.76

Operating Income
-10.76

Net Income Before Taxes
-10.96

Net Income
-10.96

Diluted Normalized EPS
-1.45

Period
2019

Total Revenue
0.07

Selling/ General/ Admin Expenses Total
0.25

Depreciation/ Amortization
9.89

Other Operating Expenses Total
0.47

Total Operating Expense
10.65

Operating Income
-10.58

Net Income Before Taxes
-8.79

Net Income
-8.79

Diluted Normalized EPS
-1.39

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Transgene Biotek Technical

Moving Average SMA

5 Day4.34
10 Day4.3
20 Day4.2

50 Day4.01
100 Day4.04
300 Day5.5

Transgene Biotek Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Veerhealth Care
18.54
0.26
1.42
27
9.29
36.94

Ang Lifesciences India
28
0.17
0.61
62.75
21.03
36.56

Transgene Biotek
4.42
-0.09
-2
10.84
3.22
29.07

Panjon
18.91
-0.23
-1.2
40.18
17.61
32.1

Aryavan Enterprise
45
-0.02
-0.04
69.74
31.57
25.92

Transgene Biotek Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

07-May-25
Audited Results

24-Jan-25
Quarterly Results

12-Nov-24
Quarterly Results & A.G.M.

10-Aug-24
Quarterly Results

30-May-24
Audited Results

14-Feb-24
Quarterly Results

14-Nov-23
Quarterly Results & Others

05-Aug-23
Quarterly Results & Others

30-May-23
Audited Results

14-Feb-23
Quarterly Results

Meeting Date
Announced on
Purpose

05-Dec-24
12-Nov-24
AGM

30-Dec-23
16-Nov-23
AGM

View All

Company Profile

ABOUT Transgene Biotek

Industry Biotechnology & Drugs
ISIN INE773D01018
BSE Code 526139

Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products includes oncology, autoimmunity, drug delivery and biogenetics. The Company offers TrabiAAV, which is a platform for the delivery of micro-ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL drug is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203 drug is used to strengthen cell-mediated immunity and complete the elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus drug suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

MANAGEMENT

K. Koteswara Rao Managing Director

TRANSGENE BIOTEK SUMMARY

Transgene Biotek is trading 2.00% lower at Rs 4.42 as compared to its last closing price. Transgene Biotek has been trading in the price range of 4.51 & 4.42. Transgene Biotek has given -35.29% in this year & 3.03% in the last 5 days.

The company posted a net profit of -0.71 Crores in its last quarter.

Listed peers of Transgene Biotek include Veerhealth Care (1.42%), Ang Lifesciences India (0.61%), Transgene Biotek (-2%) etc.

Transgene Biotek has a 0% promoter holding & 0% public holding.

FAQs about Transgene Biotek

Transgene Biotek is trading at 4.42 as on 27 Jun, 2025 3:15:00 PM. This is -2.00% lower as compared to its previous closing price of 4.51

The market capitalization of Transgene Biotek is 29.07 Cr as on 27 Jun, 2025 3:15:00 PM.

The 52 wk high for Transgene Biotek is 10.84 whereas the 52 wk low is 3.22

Transgene Biotek can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: 49.32
Dividend Yield: 0%
D/E ratio: -

Transgene Biotek reported a net profit of -0.68 Cr in 2025.

Transgene Biotek Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Transgene Biotek Share Price

Price Range

Key Metrics

Transgene Biotek Analysis

Transgene Biotek Financials

Forecast

Forecast

Forecast

Transgene Biotek Technical

Transgene Biotek Peers

Transgene Biotek Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Transgene Biotek

MANAGEMENT

TRANSGENE BIOTEK SUMMARY

FAQs about Transgene Biotek

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue